U.S. Stem Cells Industry

The U.S. stem cells market size was estimated at USD 4.79 billion in 2023 and is expected to grow at a CAGR of 9.5% from 2024 to 2030. Increase in acceptance of regenerative medicine and rise in number of regulatory approvals of stem cell therapies are expected to drive the market. Growing demand for regenerative medicines, increase in healthcare expenditure, an increase in the incidence of genetic disorder and cancer are the major factors driving the market. Moreover, preservation of stem cells for future treatment with the help of public & private umbilical cord & tissue banking has proved to be profitable in the past; this practice has already gained immense acceptance offering significant momentum to the stem cells market.

The U.S. accounted for over 32.4% of the global stem cells market in 2023. The market is anticipated to be propelled by the escalating progress in precision medicine, the expansion of cell therapy production facilities, and an increasing count of clinical trials. The recent breakthroughs in stem cell therapeutics and tissue engineering have the potential to become a focal point for treating numerous diseases. In addition, the growing demand for stem cell banking and the surge in research activities related to the production, storage, and characterization of stem cells are predicted to boost the market’s revenue growth. The technological advancements in the primary and ancillary markets for stem cell usage further strengthen the anticipated demand growth for stem cells in the forecast period.

Gather more insights about the market drivers, restrains and growth of the U.S. Stem Cells market

The COVID-19 pandemic positively impacted the market, sparking increased interest in clinical trials for products used in treating the virus. Regenerative medicine, particularly stem cell therapies, emerged as potential treatments, reducing mortality and infection rates. For instance, in 2020, COVID-19 patients received stem cell infusions, proving safe and reliable. This has fueled the growing demand for regenerative medicines, which are widely used in treating various diseases and are increasingly sought after for early disease detection and prevention, especially among the aging population.

Regenerative medicines, with their wide-ranging applications in treating various diseases, including neurology, oncology, hepatology, diabetes, injuries, hematology, and orthopedics, are seeing increased demand, particularly for early disease detection and prevention among the aging population. These medicines aid in cell function restoration and are expected to offer effective therapies for chronic conditions due to rapid advancements in the field. A notable development is the March 2022 partnership between Wipro Ltd and Pandorum Technologies, aimed at developing technologies to expedite time-to-market and improve patient outcomes in clinical trials and regenerative medicine R&D. Pandorum will leverage Wipro’s AI capabilities to enhance patient outcomes in regenerative medicine and advanced therapeutics.

Key U.S. Stem Cells Company Insights

The U.S. stem cells market is characterized by the existence of both established companies and startups that concentrate on specialized therapeutics. Major market participants are innovating new products and engaging in partnerships to expand their product range, customer base, and global footprint. These tactics are anticipated to stimulate market growth in the future as more competitors join the market and strive to consolidate their market standing. Notable market players include Pluristem Therapeutics, Inc., STEMCELL Technologies, Inc., Bristol-Myers Squibb, Lisata Therapeutics, Cellular Engineering Technologies, Lineage Cell Therapeutics, BrainStorm Cell Therapeutics, among others.

Key U.S. Stem Cells Companies:

  • Thermo Fisher Scientific, Inc.
  • STEMCELL Technologies Inc.
  • Merck KGaA
  • CellGenix GmbH
  • PromoCell GmbH
  • Takara Bio
  • Lonza
  • Cellartis AB
  • ATCC
  • AcceGen

Recent Developments

  • In February 2024, Takara Bio has revealed their intention to introduce two essential tools for cancer research: kits for automated single-cell total RNA-seq and DNA-seq library preparation. Utilizing the innovative Shasta™ technologies, Takara Bio is set to launch pioneering large-scale solutions capable of detecting significant genetic events overlooked by other technologies. The increased throughput and sensitivity offered by these solutions lead to greater confidence in the results and enable breakthroughs that were previously unattainable.
  • In October 2023, Thermo Fisher Scientific, Inc. introduced several innovative products to the market. These include the Thermo Scientific Glacios 2 Cryo-TEM, which is designed to speed up structure-based drug discovery. They have also launched the Gibco CTS DynaCellect Magnetic Separation System, a tool aimed at improving the production of cell therapies. In addition, they have developed the SeCore CDx HLA Sequencing System.
  • In September 2022, Gamida Cell Ltd. announced that it would present the follow-up data of patients treated with omidubicel. The presentation at the Society of Hematologic Oncology (SOHO) of the results is anticipated to develop positive brand value for the company among its peer companies and other stakeholders.

Order a free sample PDF of the U.S. Stem Cells Market Intelligence Study, published by Grand View Research.